The Sinopharm and WuXi AppTec-backed, complement system-focused drug developer has hauled in $53.3m of new funding after emerging from stealth late last year.

Kira Pharmaceuticals, a US-headquartered inflammatory, autoimmune disease and cancer drug developer backed by pharmaceutical firm Sinopharm, has raised $53.5m for the first close of its series B-plus round.

The round was co-led by investment manager RA Capital Management and healthcare investment firm Vivo Capital and also featured Foresite Capital, APlus Partners, Quan Capital and Qiming Venture Partners USA.

Founded in 2017, Kira focuses on the development of therapies for cancer, inflammatory and autoimmune diseases that will target the complement system,…